Jugular plasma concentrations of 13,14-dihydro-15-keto-prostaglandin F2 alpha in prepubertal beef heifers treated with progestogen then challenged with oxytocin.
Prepubertal Angus crossbred heifers (n = 24) between 8 and 10 mo of age were used to determine if progestogen treatment would enhance jugular concentrations of 13,14-dihydro-15-keto-prostaglandin F2 alpha (PGFM) after oxytocin (OT) injections. Heifers were stratified by age and weight and allotted to randomized treatments in a 2 x 2 factorial arrangement. Heifers were treated with either a norgestomet (NOR) implant (6 mg) for 9 d or no implant (0 mg; BLK). On d 8 of NOR treatment, jugular veins were catheterized and, on d 9, blood samples were collected every 15 min for 165 min. The first four samples were used to determine basal PGFM concentrations (an indirect measure of uterine PGF2 alpha release). After collection of the fourth sample, either OT (100 IU) or saline (0 IU; SAL) was injected via the jugular catheter. After the 165-min sample was collected, NOR implants were removed. Beginning 48 h after implant removal, a second 165- min blood sampling period was initiated. Average progesterone concentrations were less than 1 ng/ml during both bleeding periods. Within treatment, PGFM concentrations were similar between the first and second sampling periods; therefore, data within treatment were combined. Basal PGFM concentrations were higher (P < .01) in NOR-treated than in BLK heifers. Oxytocin did not increase PGFM concentrations in BLK-OT heifers; however, a marked increase in PGFM was detected in the NOR-OT heifers in response to oxytocin. Average PGFM concentration was greatest (P < .0001) in NOR-OT heifers, and PGFM profiles differed (P < .0001) between NOR-OT and each of the other treatment groups. Results from this study indicate that NOR increases basal PGFM and may "condition" the uterus to respond to OT in prepubertal heifers.
Del Vecchio
R P
RP
Virginia Polytechnic Institute and State University, Blacksburg 24061-0306.
Custer
E E
EE
Beal
W E
WE
Lewis
G S
GS
D000818:Animals; D002417:Cattle; D015237:Dinoprost / Q000031:analogs & derivatives* / Q000097:blood; D004357:Drug Synergism; D005260:Female; D007601:Jugular Veins; D010121:Oxytocin / Q000494:pharmacology*; D011282:Pregnenediones / Q000494:pharmacology*; D011374:Progesterone / Q000378:metabolism*; D045167:Progesterone Congeners / Q000494:pharmacology*; D012741:Sexual Maturation / Q000502:physiology*
D011282:Pregnenediones; D045167:Progesterone Congeners; C008228:15-keto-13,14-dihydroprostaglandin F2alpha; C100284:norgestomet; D011374:Progesterone; D010121:Oxytocin; D015237:Dinoprost